SARS‐CoV‐2 infection as a trigger of humoral response against apolipoprotein A‐1
Authors:
Open Access
- 4 August 2021
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 51 (11) , e13661
Abstract
Background: Unravelling autoimmune targets triggered by SARS‐CoV‐2 infection may provide crucial insights into the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining (a) the association between anti‐SARS‐CoV‐2 and anti‐apoA‐1 humoral response and (b) the degree of linear homology between SARS‐CoV‐2, apoA‐1 and Toll‐like receptor 2 (TLR2) epitopes.Design: Bioinformatics modelling coupled with mimic peptides engineering and competition experiments were used to assess epitopes sequence homologies. Anti‐SARS‐CoV‐2 and anti‐apoA‐1 IgG as well as cytokines were assessed by immunoassays on a case‐control (n = 101), an intensive care unit (ICU; n = 126) and a general population cohort (n = 663) with available samples in the pre and post‐pandemic period.Results: Using bioinformatics modelling, linear sequence homologies between apoA‐1, TLR2 and Spike epitopes were identified but without experimental evidence of cross‐reactivity. Overall, anti‐apoA‐1 IgG levels were higher in COVID‐19 patients or anti‐SARS‐CoV‐2 seropositive individuals than in healthy donors or anti‐SARS‐CoV‐2 seronegative individuals (P < .0001). Significant and similar associations were noted between anti‐apoA‐1, anti‐SARS‐CoV‐2 IgG, cytokines and lipid profile. In ICU patients, anti‐SARS‐CoV‐2 and anti‐apoA‐1 seroconversion rates displayed similar 7‐day kinetics, reaching 82% for anti‐apoA‐1 seropositivity. In the general population, SARS‐CoV‐2‐exposed individuals displayed higher anti‐apoA‐1 IgG seropositivity rates than nonexposed ones (34% vs 16.8%; P = .004).Conclusion: COVID‐19 induces a marked humoral response against the major protein of high‐density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long‐term COVID‐19 prognosis assessment and warrant further scrutiny in the current COVID‐19 pandemic.Keywords
All Related Versions
Funding Information
- Fondation Ernst et Lucie Schmidheiny
This publication has 50 references indexed in Scilit:
- CD14 as a Mediator of the Mineralocorticoid Receptor–Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on CardiomyocytesEndocrinology, 2015
- The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?PLOS ONE, 2015
- Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4Thrombosis and Haemostasis, 2015
- Definition of Human Apolipoprotein A-I Epitopes Recognized by Autoantibodies Present in Patients with Cardiovascular DiseasesJournal of Biological Chemistry, 2014
- Anti‐apolipoprotein A‐1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complexJournal of Internal Medicine, 2012
- Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarctionEuropean Heart Journal, 2010
- Autoimmunity and HIVCurrent Opinion in Infectious Diseases, 2009
- Lipid rafts are involved in SARS-CoV entry into Vero E6 cellsBiochemical and Biophysical Research Communications, 2008
- Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated LipopeptideCell, 2007
- The Central Helices of ApoA-I Can Promote ATP-binding Cassette Transporter A1 (ABCA1)-mediated Lipid EffluxJournal of Biological Chemistry, 2003